{"entity":{"id":"nct07306286","kind":"trial","name":"Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by Ruijin Hospital, now recruiting.","summary":"Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy is a phase 2, interventional study registered as NCT07306286 by Ruijin Hospital, with a registry enrolment figure of 20 participants, started 2025-12-15 and due to reach its primary completion in 2027-08-01. Interventions recorded: Cryoablation; Dual-Function Antibody PD-1/CTLA-4. Conditions listed: Pancreatic Adenocarcinoma Locally Advanced. Primary outcome: Overall Survival. Pancreatic eligibility wording from the registry: \"* Pathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium), with clinical records indicating locally advanced pancreatic cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07306286","url":"https://clinicaltrials.gov/study/NCT07306286"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07306286","phase":"2","setting":"A Single-Arm, Open-Label Clinical Study of Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 (Apalulizumab) for the Treatment of Locally Advanced Pancreatic Cancer Following Failure of First-Line AG Therapy","sponsor":"Ruijin Hospital","participation":[{"nct":"NCT07306286","source":"https://clinicaltrials.gov/study/NCT07306286","fetchedAt":"2026-10-07T16:55:39.854Z","studySha256":"d23525b603ac3fb5ccf19cf4acf79185f06b5ccdf91ee38cf1a26fa47bf057ad","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-29","leadSponsor":"Ruijin Hospital","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":20,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-12-15","startedType":"estimated","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07306286/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}